Phase 2 study of temozolomide and Caelyx in patients with recurrent glioblastoma multiforme
Authors:
- Mark A. RosenthalMRMark A. Rosenthal
- Shirley S. WongSWShirley S. Wong
- David M. AshleyDADavid M. Ashley
- Anne-Marie WoodsAWAnne-Marie Woods
- Anthony DowlingADAnthony Dowling
- Lawrence M. CherLCLawrence M. Cher
Open Access
- 1 January 2004
- journal article
- clinical trial
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 6 (1) , 38-43
Abstract
Temozolomide has established activity in the treatment of recurrent glioblastoma multiforme (GBM). Caelyx (liposomal doxorubicin) has established actKeywords
This publication has 27 references indexed in Scilit:
- Neuro-oncology clinical trials: Promise and pitfallsAnnals of Oncology, 2001
- PCV chemotherapy for recurrent glioblastoma multiformeNeurology, 2001
- High intratumoural accumulation of stealth® liposomal doxorubicin (Caelyx®) in glioblastomas and in metastatic brain tumoursBritish Journal of Cancer, 2000
- Schedule-dependent activity of temozolomide plus CPT-11 against a human central nervous system tumor-derived xenograft.2000
- A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapseBritish Journal of Cancer, 2000
- Temozolomide and treatment of malignant glioma.2000
- Phase II Study of Combination Taxol and Estramustine Phosphate in the Treatment of Recurrent Glioblastoma MultiformeJournal of Neuro-Oncology, 2000
- Multicenter Phase II Trial of Temozolomide in Patients With Anaplastic Astrocytoma or Anaplastic Oligoastrocytoma at First RelapseJournal of Clinical Oncology, 1999
- Outcomes and Prognostic Factors in Recurrent Glioma Patients Enrolled Onto Phase II Clinical TrialsJournal of Clinical Oncology, 1999
- Sequential administration of temozolomide and fotemustine: Depletion of O6-alkyl guanine-DNA transferase in blood lymphocytes and in tumoursAnnals of Oncology, 1999